Treatment News : New Kidney Risk Score System May Guide HIV Med Choices

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 7, 2014

New Kidney Risk Score System May Guide HIV Med Choices

Researchers have developed a scoring system to estimate the five-year risk for developing kidney disease among HIV-positive men, an aid that can help guide decision-making about the best antiretroviral (ARV) regimen for people with HIV, aidsmap reports. Publishing their findings in the journal AIDS, the investigators developed their risk score based on the medical records of 21,590 HIV-positive males who began taking ARVs between 1997 and 2010.

When developing the scoring system, the researchers included numerous factors linked to kidney disease development, including high glucose, triglyceride and systolic blood pressure levels, as well as hypertension, advanced age, protein in the urine and low CD4 levels.

A total of 7.7 percent of the men in the group who were taking Viread (tenofovir, which is a component of Truvada and is associated with an increased risk of kidney damage) developed chronic kidney disease during five years of follow-up, compared with 3.8 percent of men taking an ARV regimen that did not include the drug.

If men scored a zero on the risk scale and were not taking Viread, they had a 1 percent risk of developing kidney disease over a five-year period, compared with a 16 percent risk for non-Viread-treated men whose risk scores were nine or higher. Among the men who were on Viread, the five-year risk of kidney damage jumped from 1.4 percent with a score of zero to 21.4 percent with a nine or above risk score.

To read the aidsmap story, click here.

To read the journal abstract, click here.

Search: Kidney damage, risk score, aidsmap, Viread, tenofovir, Truvada.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    InDefaultOf
    Seattle
    Washington


    sefarady
    New York
    California

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.